Navigation Links
RVX-208 Data Demonstrates Increase in Functional HDL Particles
Date:11/10/2008


Prebeta-HDL generation and improved HDL functionality are distinguishing

factors

TSX Exchange Symbol: RVX

NEW ORLEANS, LA, Nov. 10 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today key scientific data was presented in an oral presentation highlighting the novel features of RVX-208 at the American Heart Association Scientific Meeting. The presentation titled "Compound RVX-208 Modulates HDL-C Levels and Function in Non-human Primates and in Early Human Trials" was presented by Dr. Jacques Genest.

Dr. Jacques Genest, MD, Director of the Division of Cardiology at McGill University Health Centre/Royal Victoria Hospital said, "We continue to be excited about the data that is being generated for RVX-208. It is important that our colleagues have access to this promising data which is why we have presented at this prominent conference. Resverlogix's novel drug demonstrated the ability to increase the production of ApoA-I and functional HDL. Notably we saw increases in prebeta-HDL particles, which improve HDL's ability to mediate cholesterol efflux."

"Today we presented interesting and consistent data from African Green monkey studies and our Phase 1a human clinical trial at the AHA," stated Dr. Jan Johansson, MD, Ph.D., Senior Vice President, Medical Affairs of Resverlogix. "The pharmacodynamic data from human healthy volunteers of which the majority had low HDL demonstrated that we have seen significant increases in ApoA-I production and HDL functionality, consistent with previous findings in the African Green monkey studies. Further investigation of the effect of RVX-208 on the HDL metabolic pathway is ongoing in humans and animals to establish the mechanisms of action and therapeutic potential in treating atherosclerotic cardiovascular disease."

During the presentation Dr. Genest reported that in an African Green monkey study treatment with RVX-208 resulted in a highly
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. RVX-208 Exploratory Study Illustrates Early Potential for Alzheimers Disease
2. International Steering Committee for RVX-208 IVUS Trial Formed
3. Phase 1b/2a Program Commences for RVX-208
4. Industry Leaders Select Resverlogixs RVX-208
5. Dosing for RVX-208 Phase 1a Clinical Study Completed
6. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
7. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
8. Study From the University of Texas M.D. Anderson Cancer Center Demonstrates That AHCC(R) is Safe in Combination With Most Chemotherapeutic Agents
9. Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
10. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
11. SuperGens MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... York , September 23, 2014 ... leading provider of  Closed System Transfer     Devices ... exclusive partnership with Taiwanese distributor MedFront Medical Technology Corporation.  Equashield,s ... in Taiwan , ... as the company continues to expand globally, and ...
(Date:9/23/2014)... 23, 2014 Dr. Williams says, “Find ... on healthcare offers a three phase process that can ... delivery system that would go far beyond anything previously ... the delivery of healthcare.” , “Every effort to improve ... to provide discernable progress throughout that system because all ...
(Date:9/23/2014)... England , September 23, 2014 ... launched with funding from Imperial Innovations, Cambridge Innovation Capital ... Inivata, a clinical cancer genomics company focused on ... analysis to improve cancer testing and treatment, today ... round led by Imperial Innovations and including Cambridge ...
(Date:9/22/2014)... and SANTA CLARA, Calif. , Sept. ... WBMD ), the leading source of health information, ... survey that provide novel insights regarding physician and ... and care.  Dr. Eric Topol , a leading ... who serves as both Editor-in-Chief of Medscape and Chief ...
Breaking Biology Technology:Equashield Enters Taiwan Following Expansion to Australia, Japan, China 2Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 2WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 3WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 4
... Scheduled for Thursday, May 15th at 5 PM ... ... IMRX ) today announced that the Company has postponed its live,webcast and ... quarter 2008 financial results; this call was originally,scheduled for Tuesday, May 13, 2008, ...
... Interleukin Genetics,Inc. (Amex: ILI ) announced today that ... Rodman and Renshaw 5th Annual Global,Healthcare Conference on Monday ... The conference will be held at Le Meridien Beach ... of the presentation will be available on the,Investors section ...
... BETHLEHEM, Pa., May 13 Particle Sciences has expanded,its ... ft Class 1000 (ISO 6),clean room. The space also ... was added to the existing 15,000 sq ft facility ... manufacturing,especially that of semisolids, suspensions and dispersions. "This,investment is ...
Cached Biology Technology:Interleukin Genetics to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2
(Date:9/23/2014)... 2014 Research and Markets  has announced ... and Opportunities, 2019" report to their offering. ... enhancing security and protection in private as well as ... country,s government is focusing on using biometric systems to ... national IDs that are of crucial importance to the ...
(Date:9/23/2014)... CORAL SPRINGS, Florida , September 23, 2014 ... listings for innovative companies in tech sector position for significant ... generation products & services.  Companies in focus today are: NXT-ID, ... (NYSE: BABA ), Mobileye N.V. (NYSE: ... ReWalk Robotics Ltd. (NASDAQ: RWLK) NXT-ID, Inc. (NASDAQ: ...
(Date:9/23/2014)... have parasitic DNA fragments called "jumping genes" that insert ... process. And that phenomenon can result in age-related diseases ... Rochester now report that the "jumping genes" in mice ... protein stops keeping them in check in order to ... published today in Nature Communications , Professor of ...
Breaking Biology News(10 mins):India Biometrics Market Forecast and Opportunities, 2019 2India Biometrics Market Forecast and Opportunities, 2019 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 2Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 4Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 5Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 6Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 7A multi-function protein is key to stopping genomic parasites from 'jumping' 2
... the 20th EORTCNCIAACR Symposium on "Molecular Targets and ... from Tuesday 21 October-Friday 24 October. Today ... accommodation via the official local agent if you ... the European Organisation for the Research and Treatment ...
... national trial of a catheter-based treatment for deep ... in combination with clot removal devices to prevent ... of a blood clot in a leg vein). ... permanent damage to the veins, resulting in debilitating ...
... Wayne State University have tested a breast cancer vaccine ... even cancers resistant to current anti-HER2 therapy - without ... 15 issue of Cancer Research, a journal ... vaccine could treat women with HER2-positive, treatment-resistant cancer or ...
Cached Biology News:Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics 2Pivotal national trial uses newest interventional radiology treatment to bust blood clots in legs 2Pivotal national trial uses newest interventional radiology treatment to bust blood clots in legs 3Vaccine against HER2-positive breast cancer offers complete protection in lab 2Vaccine against HER2-positive breast cancer offers complete protection in lab 3
... BacMagic™ DNA Kit provides a positive selection ... recombinant protein expression in insect cells. The ... generating recombinant baculoviruses by eliminating the time-consuming ... is an AcNPV genome with a portion ...
... CLS number is a new product number, ... If showing no availability yet, please order ... contact customer service for assistance. ... Dim: surface area 500 cm 2 ...
Mouse Anti-Human Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4 Monoclonal Antibody Family: New...
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
Biology Products: